Welcome to our dedicated page for Tactile Systems news (Ticker: TCMD), a resource for investors and traders seeking the latest updates and insights on Tactile Systems stock.
Tactile Systems Technology Inc (NASDAQ: TCMD) delivers innovative medical solutions for chronic conditions through advanced home therapy devices. This news hub provides investors and healthcare professionals with essential updates on corporate developments, clinical advancements, and regulatory milestones.
Track key updates including quarterly earnings reports, new product clearances, partnership announcements, and clinical study results. Our curated collection ensures access to verified press releases and objective market analysis related to lymphedema management and venous insufficiency treatments.
Discover comprehensive coverage of TCMD's operational progress, including FDA submissions, insurance reimbursement developments, and technological innovations in pneumatic compression therapy. All content is maintained to meet strict journalistic standards for accuracy and relevance in the medical device sector.
Bookmark this page for streamlined access to Tactile Systems' latest announcements and historical performance data. Check regularly for updates that could impact understanding of the company's market position in home-based chronic care solutions.
Tactile Systems Technology, Inc. reported a 4% increase in total revenue to $61.1 million for Q1 2024. The company's lymphedema product revenue grew 5% while airway clearance product revenue decreased by 4%. Net loss was $2.2 million versus $1.9 million in Q1 2023. Adjusted EBITDA rose to $1.0 million from $0.5 million in Q1 2023. The company also completed a clinical trial and published a peer-reviewed study on its products.
FAQ
What is the current stock price of Tactile Systems (TCMD)?
What is the market cap of Tactile Systems (TCMD)?
